➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Medtronic
McKinsey
Harvard Business School
Dow

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MYRBETRIQ

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Myrbetriq

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00410514 A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO) Completed Astellas Pharma Inc Phase 2 2006-12-01 This study examined the safety, tolerability, and efficacy of mirabegron (YM178) compared to placebo.
NCT00688688 Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-04-01 The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active comparator.
NCT00689104 Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder Completed Astellas Pharma Inc Phase 3 2008-04-01 The study is intended to test efficacy, safety and tolerability of two doses of Mirabegron against placebo and compare the efficacy and safety with active comparator in patients with symptoms of overactive bladder.
NCT01340027 A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder Completed Astellas Pharma Europe B.V. Phase 2 2011-03-01 The purpose of this study is to examine how well two medicines in combination (solifenacin succinate and mirabegron) work in the treatment of bladder problems over a 12-week period.
NCT01638000 A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. Completed Astellas Pharma Europe Ltd. Phase 3 2012-06-01 The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of efficacy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Myrbetriq

Condition Name

Condition Name for Myrbetriq
Intervention Trials
Overactive Bladder 12
Urinary Bladder, Overactive 5
Urinary Bladder Overactive 4
Urologic Diseases 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Myrbetriq
Intervention Trials
Urinary Bladder, Overactive 20
Urologic Diseases 6
Urinary Bladder Diseases 6
Lower Urinary Tract Symptoms 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Myrbetriq

Trials by Country

Trials by Country for Myrbetriq
Location Trials
United States 190
Canada 37
Denmark 9
Germany 9
United Kingdom 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Myrbetriq
Location Trials
New York 9
Massachusetts 8
Florida 8
California 8
Arizona 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Myrbetriq

Clinical Trial Phase

Clinical Trial Phase for Myrbetriq
Clinical Trial Phase Trials
Phase 4 9
Phase 3 11
Phase 2/Phase 3 1
[disabled in preview] 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Myrbetriq
Clinical Trial Phase Trials
Completed 15
Recruiting 13
Not yet recruiting 10
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Myrbetriq

Sponsor Name

Sponsor Name for Myrbetriq
Sponsor Trials
Astellas Pharma Europe B.V. 7
Astellas Pharma Inc 6
Astellas Pharma Global Development, Inc. 4
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Myrbetriq
Sponsor Trials
Industry 26
Other 24
NIH 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
AstraZeneca
McKinsey
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.